Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07322341 · ClinicalTrials.gov registry record · Phase 2
SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
A Phase 2 study, sponsored by University of Washington.
- Not yet
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT07322341 is a Phase 2 study that has not yet begun recruiting, run by University of Washington. The registered enrollment target is 32 participants.
The verdict
NCT07322341, a Phase 2 study, has not yet begun recruiting, sponsored by University of Washington.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This phase II trial tests how well SX-682 and atezolizumab works for the treatment of non-small cell lung cancer (NSCLC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic), and has come back after a period of improvement (recurrent). SX-682 blocks proteins that may be able to stimulate the immune system to kill and eliminate tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving SX-682 and atezolizumab may be effective for the treatment of advanced or metastatic, recurrent NSCLC.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- BIOLOGICAL Atezolizumab
- PROCEDURE Magnetic Resonance Imaging
- DRUG CXCR1/2 Inhibitor SX-682
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2031-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07322341
The ClinicalTrials.gov registry entry for NCT07322341 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07322341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07322341 about?
NCT07322341 is a clinical study titled "SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer". This phase II trial tests how well SX-682 and atezolizumab works for the treatment of non-small cell lung cancer (NSCLC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary sit...
What is the current status of trial NCT07322341?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2026-09-01. Estimated completion is 2031-11-01.
What interventions are being tested in trial NCT07322341?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Atezolizumab (BIOLOGICAL), Magnetic Resonance Imaging (PROCEDURE), CXCR1/2 Inhibitor SX-682 (DRUG).
Who is sponsoring clinical trial NCT07322341?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.